Objective: To evaluate the effectiveness and safety of bifendatatum for chronic hepatitis B by systematic review.Methods: Publications on bifendatatum treatment for chronic hepatitis B were collected.Subgroup analysis was performed of interventions described in the literature;analyses were performed according to the inclusion and exclusion criteria developed over the past 30 years.Liver biochemical indices(reduction and normalization rate of alanine aminotransferase),immunological response indicators(negative conversion rate of HBsAg and HBeAg),virological indicators(negative conversion rate and reduction of HBV DNA) and liver fibrosis(reduction of laminin,hyaluronic acid,collagen Ⅳ and procollagen Ⅲ) were systematically evaluated.Results: A total of 7 studies involving 1253 patients met the inclusion criteria.Of these,one study reported randomization method,the results of systematic review showed: In terms of reducing ALT,a bifendate group,a bifendate plus a traditional Chinese medicine group and a silymarin group were significantly better than the control group.In terms of the rate of HBV DNA seroconversion,bifendate plus silymarin group was significantly higher than silymarin group;in terms of the reduction of HBV DNA,there was no significant differences between the group of bifendate dripping pills plus oleanic acid and glucurolactone acid tablets and the group of oleanic acid plus glucurolactone acid tablets;in terms of the rate of HBsAg and HBeAg seroconversion,bifendate group was significantly higher than oleanic acid group;in terms of reducing the index of hepatic fibrosis,bifendate dripping pills plus oleanic acid and glucurolactone acid tablets group was significantly better than the control group.Conclusion: The effect of bifendatatum on improving ALT,virological indicators,immunological response,and propensity to liver fibrosis in chronic hepatitis B is significant.Therefore,bifendatatum is really a medicine worthy of further promotion.